Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.

Lisa A BeckRobert BissonnetteMette DeleuranTakeshi NakaharaRyszard GalusAnna ColemanGuy GherardiJing XiaoRobert DingmanChristine XuElena AvetisovaAriane Dubost-BramaArsalan Shabbir

Published in: JAMA dermatology (2024)

In this study, there was sustained safety and efficacy of continuous long-term dupilumab treatment for adults with moderate to severe AD.

Keyphrases

atopic dermatitis
early onset
clinical trial
high intensity
randomized controlled trial
squamous cell carcinoma